Novel Cancer Therapy Based On A Telomerase Reverse Transcriptase Variant

Janine Santos (Inventor)

Research output: Innovation

Abstract

Invention Summary:

Telomeres, the protein-DNA structures located on the ends of eukaryotic chromosomes, are required for chromosome stability during DNA replication. Studies have demonstrated that telomere length may serve to limit the replication potential of cells, hence serve as a barrier to immortalization and carcinogenesis. Telomerase plays a key role in maintaining telomere function and activity by catalyzing telomere replication. In human, telomerase activation is observed in 90% of all tumors. Therefore, telomerase is a bona fide target for development of agents directed to cancer therapy.

The inventors have generated a novel mutant of human telomerase catalytic core (LAhTERT). Forced expression of LAhTERT in prostate cancer, cervical carcinoma, and squamous carcinoma cell lines results in a delay in cell cycle progression and renders cells more sensitive to mitochondrial DNA damage and apoptosis induced by oxidative stress (which may be induced by H 2 O 2 , radiation, and other genotoxic agents). Targeted delivery of LAhTERT may be achieved by linking LAhTERT peptides or expression vectors with antibodies or nanoparticles that specifically target cancer cells or other desired cell types.

Market Applications:
  • Treatment for cancer and other hyperplasia diseases
  • Treatment for inflammatory and autoimmune diseases

Intellectual Property & Development Status:

United States Patent Number 8,362,209 granted on January 29, 2013

Original languageEnglish (US)
StatePublished - Mar 2014
Externally publishedYes

Fingerprint

Telomerase
Telomere
Neoplasms
Inventors
Intellectual Property
Chromosomal Instability
Therapeutics
DNA Replication
Mitochondrial DNA
Nanoparticles
Autoimmune Diseases
DNA Damage
Hyperplasia
Squamous Cell Carcinoma
Catalytic Domain
Prostatic Neoplasms
Cell Cycle
Carcinogenesis
Oxidative Stress
Chromosomes

Keywords

  • Autoimmune
  • Biomaterials
  • Oncology

Cite this

@misc{ea8b2c85548342f385c75c173073b304,
title = "Novel Cancer Therapy Based On A Telomerase Reverse Transcriptase Variant",
abstract = "Invention Summary: Telomeres, the protein-DNA structures located on the ends of eukaryotic chromosomes, are required for chromosome stability during DNA replication. Studies have demonstrated that telomere length may serve to limit the replication potential of cells, hence serve as a barrier to immortalization and carcinogenesis. Telomerase plays a key role in maintaining telomere function and activity by catalyzing telomere replication. In human, telomerase activation is observed in 90{\%} of all tumors. Therefore, telomerase is a bona fide target for development of agents directed to cancer therapy. The inventors have generated a novel mutant of human telomerase catalytic core (LAhTERT). Forced expression of LAhTERT in prostate cancer, cervical carcinoma, and squamous carcinoma cell lines results in a delay in cell cycle progression and renders cells more sensitive to mitochondrial DNA damage and apoptosis induced by oxidative stress (which may be induced by H 2 O 2 , radiation, and other genotoxic agents). Targeted delivery of LAhTERT may be achieved by linking LAhTERT peptides or expression vectors with antibodies or nanoparticles that specifically target cancer cells or other desired cell types. Market Applications: Treatment for cancer and other hyperplasia diseases Treatment for inflammatory and autoimmune diseases Intellectual Property & Development Status: United States Patent Number 8,362,209 granted on January 29, 2013",
keywords = "Autoimmune, Biomaterials, Oncology",
author = "Janine Santos",
year = "2014",
month = "3",
language = "English (US)",
type = "Patent",

}

Novel Cancer Therapy Based On A Telomerase Reverse Transcriptase Variant. / Santos, Janine (Inventor).

Research output: Innovation

TY - PAT

T1 - Novel Cancer Therapy Based On A Telomerase Reverse Transcriptase Variant

AU - Santos, Janine

PY - 2014/3

Y1 - 2014/3

N2 - Invention Summary: Telomeres, the protein-DNA structures located on the ends of eukaryotic chromosomes, are required for chromosome stability during DNA replication. Studies have demonstrated that telomere length may serve to limit the replication potential of cells, hence serve as a barrier to immortalization and carcinogenesis. Telomerase plays a key role in maintaining telomere function and activity by catalyzing telomere replication. In human, telomerase activation is observed in 90% of all tumors. Therefore, telomerase is a bona fide target for development of agents directed to cancer therapy. The inventors have generated a novel mutant of human telomerase catalytic core (LAhTERT). Forced expression of LAhTERT in prostate cancer, cervical carcinoma, and squamous carcinoma cell lines results in a delay in cell cycle progression and renders cells more sensitive to mitochondrial DNA damage and apoptosis induced by oxidative stress (which may be induced by H 2 O 2 , radiation, and other genotoxic agents). Targeted delivery of LAhTERT may be achieved by linking LAhTERT peptides or expression vectors with antibodies or nanoparticles that specifically target cancer cells or other desired cell types. Market Applications: Treatment for cancer and other hyperplasia diseases Treatment for inflammatory and autoimmune diseases Intellectual Property & Development Status: United States Patent Number 8,362,209 granted on January 29, 2013

AB - Invention Summary: Telomeres, the protein-DNA structures located on the ends of eukaryotic chromosomes, are required for chromosome stability during DNA replication. Studies have demonstrated that telomere length may serve to limit the replication potential of cells, hence serve as a barrier to immortalization and carcinogenesis. Telomerase plays a key role in maintaining telomere function and activity by catalyzing telomere replication. In human, telomerase activation is observed in 90% of all tumors. Therefore, telomerase is a bona fide target for development of agents directed to cancer therapy. The inventors have generated a novel mutant of human telomerase catalytic core (LAhTERT). Forced expression of LAhTERT in prostate cancer, cervical carcinoma, and squamous carcinoma cell lines results in a delay in cell cycle progression and renders cells more sensitive to mitochondrial DNA damage and apoptosis induced by oxidative stress (which may be induced by H 2 O 2 , radiation, and other genotoxic agents). Targeted delivery of LAhTERT may be achieved by linking LAhTERT peptides or expression vectors with antibodies or nanoparticles that specifically target cancer cells or other desired cell types. Market Applications: Treatment for cancer and other hyperplasia diseases Treatment for inflammatory and autoimmune diseases Intellectual Property & Development Status: United States Patent Number 8,362,209 granted on January 29, 2013

KW - Autoimmune

KW - Biomaterials

KW - Oncology

UR - http://rutgers.technologypublisher.com/tech/Novel_Cancer_Therapy_Based_On_A_Telomerase_Reverse_Transcriptase_Variant

M3 - Innovation

ER -